US 11,813,281 B2
Methods for improving exercise tolerance in myalgic encephalomyelitis patients
David R. Strayer, Ocala, FL (US); Diane L. Young, Ocala, FL (US); and Thomas K. Equels, Ocala, FL (US)
Assigned to AIM ImmunoTech Inc., Ocala, FL (US)
Appl. No. 17/413,387
Filed by AIM ImmunoTech Inc., Ocala, FL (US)
PCT Filed Nov. 25, 2019, PCT No. PCT/US2019/063048
§ 371(c)(1), (2) Date Jun. 11, 2021,
PCT Pub. No. WO2020/123136, PCT Pub. Date Jun. 18, 2020.
Claims priority of provisional application 62/778,935, filed on Dec. 13, 2018.
Prior Publication US 2022/0062321 A1, Mar. 3, 2022
Int. Cl. A61K 31/713 (2006.01); A61K 47/61 (2017.01); A61K 47/64 (2017.01); A61P 21/06 (2006.01)
CPC A61K 31/713 (2013.01) [A61K 47/61 (2017.08); A61K 47/645 (2017.08); A61P 21/06 (2018.01)] 16 Claims
 
1. A method for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms, the method comprising:
determining that the subject is a target subject who exhibits onset of ME/CFS symptoms between 2 to 8 years prior to treatment; and
administering to the target subject a pharmaceutical composition comprising as an active ingredient an effective amount of a therapeutic dsRNA (tdsRNA);
wherein the tdsRNA is rIn·r(C12U)n and
wherein n is an integer from 40 to 50,000.